The question often isnt whether they work - its whether theyre accessible
Advertisement Article continues below this ad About 1 in 8 adults are now taking a GLP-1 drug for obesity, disease, or both, up 6 percentage points from May 2024, according to KFF poll results released in November
5 These guidelines align with the American Diabetes Association (ADA) standards of care which also provide strong recommendations based on robust clinical trial data supporting the cardiovascular benefits of GLP-1 RAs, particularly in patients with established cardiovascular disease and chronic kidney disease (CKD)
That is why nutrient-dense meals and targeted supplementation can be helpful
You need strains with demonstrated effects on transit time and stool consistency
If a clinics complaint-resolution track record factors into your decision, this is worth weighing